Cargando…

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis

INTRODUCTION: American tegumentary leishmaniasis (ATL), which can present as either cutaneous (CL) or mucosal leishmaniasis (ML), is endemic in South America, and first-line antimonial treatments are known for their wide range of adverse effects (AEs). Growing reports of drug resistance increase the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martins, Sofia Sales, Barroso, Daniel Holanda, Rodrigues, Bruna Côrtes, da Motta, Jorgeth de Oliveira Carneiro, Freire, Gustavo Subtil Magalhães, Pereira, Ledice Inácia de Araújo, Kurisky, Patrícia Shu, Gomes, Ciro Martins, Sampaio, Raimunda Nonata Ribeiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281031/ https://www.ncbi.nlm.nih.gov/pubmed/34277476 http://dx.doi.org/10.3389/fcimb.2021.700323

Ejemplares similares

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

No evidence for cardiotoxicity of miltefosine – Reply()
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

Complementary exams in the diagnosis of american tegumentary leishmaniasis
por: Gomes, Ciro Martins, et al.
Publicado: (2014)

Successful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis()()
por: Sampaio, Raimunda Nonata Ribeiro, et al.
Publicado: (2021)

Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline
por: Cincura, Carolina, et al.
Publicado: (2022)

The Presence of Leishmania braziliensis DNA in the Nasal Mucosa of Cutaneous Leishmaniasis Patients and the Search for Possible Clinical and Immunological Patterns of Disease Progression: A Cross Sectional Study
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

Field validation of a Leishmania (Leishmania) mexicana exo-antigens ELISA for diagnosing tegumentary leishmaniasis in regions of Leishmania (Viannia) predominance
por: Soares, Killarney Ataide, et al.
Publicado: (2015)

The Pentavalent Antimony Compounds in Tropical Medicine
por: Schmidt, Hans
Publicado: (1928)

PD-L1 May Mediate T-Cell Exhaustion in a Case of Early Diffuse Leishmaniasis Caused by Leishmania (L.) amazonensis
por: Barroso, Daniel Holanda, et al.
Publicado: (2018)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
por: Vincent, Isabel M., et al.
Publicado: (2015)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility
por: Santi, Ana Maria Murta, et al.
Publicado: (2021)

Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
por: Oliveira, Rodrigo A, et al.
Publicado: (2012)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

Reactions Following the Administration of the Pentavalent Compounds of Antimony: An Analysis of Cases Reported by Several Correspondents
por: Napier, L. Everard
Publicado: (1926)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions
por: Regli, Ivo B., et al.
Publicado: (2018)

Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
por: Barros, Andrea Barbieri, et al.
Publicado: (2014)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
por: Fernández, Olga Lucía, et al.
Publicado: (2014)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
por: Tayyebi, Masoumeh, et al.
Publicado: (2021)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
por: Berbert, Taisa Rocha Navasconi, et al.
Publicado: (2018)

Recurrent cutaneous leishmaniasis*
por: Gomes, Ciro Martins, et al.
Publicado: (2013)

Correction: Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Publicado: (2014)

The accuracy of the Montenegro skin test for leishmaniasis in PCR-negative patients
por: Pinheiro, Ana Bárbara Sapienza, et al.
Publicado: (2020)

Genetic variation in Interleukin-32 influence the immune response against New World Leishmania species and susceptibility to American Tegumentary Leishmaniasis
por: dos Santos, Jéssica Cristina, et al.
Publicado: (2020)

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony
por: Miranda-Verastegui, Cesar, et al.
Publicado: (2009)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
por: Santos, Marcos Ferreira, et al.
Publicado: (2019)

Interleukin 32γ (IL-32γ) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10
por: Galdino, Hélio, et al.
Publicado: (2014)

The paradox of tegumentary leishmaniasis diagnosis: How the need for accurate and modern techniques is being addressed in low income areas
por: Kurizky, Patrícia Shu, et al.
Publicado: (2018)

Multiparametric analysis of host and parasite elements in new world tegumentary leishmaniasis
por: de Carvalho, Bruna Caroline, et al.
Publicado: (2022)

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
por: Manna, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ff3g43vg72u4ngsdb55evh0gpb